AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA
EudraCT / EU CT No
2024-514139-50-00
Protocol No
C1071006
Trial information
Medical condition
MM
Trial phase
Phase 3
Sponsor
Pfizer
Start date
02/11/2023
End date
01/04/2028
Main objective
To evaluate the efficacy and safety of elranatamab+daratumumab+lenalidomide versus daratumumab+lenalidomide+dexamethasone in transplant-ineligible newly diagnosed multiple myeloma.
Locations and Contact points
Greece
Site city
Organisation name
Department name
Name
Email
Telephone number
Ioannina
University General Hospital of Ioannina
Department of Hematology, Clinical Studies Office
Eleftheria Hatzimichael
Olga Siarabi
2651099650
Cookies and your privacy
We use essential cookies to make this site work. With your consent, we also use Google Analytics cookies to measure visits and improve the site. You can change your choice at any time.